Mattson Financial Services LLC Sells 7,650 Shares of Boston Scientific Co. (NYSE:BSX)

Mattson Financial Services LLC lowered its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 25.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,494 shares of the medical equipment provider's stock after selling 7,650 shares during the quarter. Mattson Financial Services LLC's holdings in Boston Scientific were worth $1,885,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Investment Management Corp VA ADV bought a new stake in Boston Scientific during the fourth quarter worth approximately $25,000. Colonial Trust Co SC boosted its position in Boston Scientific by 1,625.0% during the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 260 shares during the period. TFC Financial Management Inc. boosted its position in Boston Scientific by 308.8% during the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 210 shares during the period. Sunbeam Capital Management LLC bought a new stake in Boston Scientific during the fourth quarter worth approximately $26,000. Finally, Ameriflex Group Inc. bought a new stake in Boston Scientific during the fourth quarter worth approximately $31,000. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Performance

BSX stock traded up $0.58 during midday trading on Friday, hitting $105.08. The stock had a trading volume of 10,524,691 shares, compared to its average volume of 6,417,660. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The stock has a 50-day simple moving average of $100.29 and a 200 day simple moving average of $97.95. Boston Scientific Co. has a 52 week low of $71.88 and a 52 week high of $107.17. The firm has a market capitalization of $155.46 billion, a price-to-earnings ratio of 84.06, a P/E/G ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The firm had revenue of $4.66 billion during the quarter, compared to analyst estimates of $4.57 billion. During the same period in the prior year, the company posted $0.56 earnings per share. The business's revenue for the quarter was up 20.9% compared to the same quarter last year. As a group, equities research analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Insider Activity

In other Boston Scientific news, CEO Michael F. Mahoney sold 164,443 shares of the firm's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $102.48, for a total transaction of $16,852,118.64. Following the transaction, the chief executive officer now owns 1,535,706 shares in the company, valued at approximately $157,379,150.88. This trade represents a 9.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Vance R. Brown sold 4,826 shares of the firm's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $95.09, for a total value of $458,904.34. Following the transaction, the senior vice president now owns 36,193 shares in the company, valued at approximately $3,441,592.37. This trade represents a 11.77% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 191,155 shares of company stock worth $19,556,047. 0.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of recent analyst reports. Argus set a $130.00 target price on Boston Scientific in a research report on Tuesday, February 18th. Royal Bank of Canada increased their price objective on Boston Scientific from $116.00 to $120.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Truist Financial increased their price objective on Boston Scientific from $113.00 to $117.00 and gave the company a "buy" rating in a research report on Thursday, April 24th. UBS Group increased their price objective on Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a research report on Friday, February 7th. Finally, Stifel Nicolaus increased their price objective on Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a research report on Thursday, February 6th. Twenty-one equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $116.00.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.